Valvular Heart Disease in Women Registry

NCT ID: NCT07196930

Last Updated: 2025-09-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-04-01

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Valvular heart disease (VHD) is a major global health issue. Untreated rheumatic heart disease persists in many regions, preventable with timely care. Higher-income countries face rising calcific valve disease from aging, worsened by VHD complications, like infective endocarditis, resulting in higher morbidity/mortality. Gender disparities in VHD remains understudied, despite inequalities in risks, diagnosis, and treatment. Prevalence varies by gender, but uneven diagnostics and therapies obscure realities. This registry will examine gender disparities from hospital admission to first outpatient follow-up, recruiting both men and women to investigate and report the study objectives.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Valvular heart disease (VHD) is a major global public health problem (1). Many regions of the world continue to grapple with the adverse consequences of untreated rheumatic heart disease, a condition that is largely preventable with timely access to diagnosis and treatment (2, 3). In turn, middle- and high-income countries have experienced a rise in the prevalence of calcific aortic and mitral disease, owing in part to population ageing (3). This public health problem is further compounded by high rates of infective endocarditis, which is associated with substantial morbidity and mortality. Yet, considerations of gender disparities have not taken centre stage in VHD research. This is despite evidence of major healthcare disparities in socioeconomic and medical risk factors, access to diagnosis, and provision of appropriate treatment (4-7). The prevalence of VHD varies by gender, but diagnostic evaluations are not equitable across the groups, which makes the true prevalence less clear. The delivery of evidence-based treatments for VHD is not equitable (8). The aim of this registry will be to examine gender differences in VHD from the time point of admission to the hospital (either elective or urgent admission) up to the first follow-up in an outpatient clinic. We will recruit both men and women in order to analyse the gender disparities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Valve Disease, Heart Gender Bias Guideline Adherence Guideline Implementation Disparities Registry

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Women with Valvular Heart Disease

Women with Valvular Heart Disease

No interventions assigned to this group

Men with Valvular Heart Disease

Men with Valvular Heart Disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients with diagnosis of any VHD according to the current ESC guidelines.
* Admission to the VHD-W Registry collaborating center.

Exclusion Criteria

* Age less than 18 years old.
* Inability to provide informed consent per local institutional and regulatory requirements.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

European Association of Cardiovascular Imaging

OTHER

Sponsor Role collaborator

Valvular Heart Disease in Women Registry

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Julia Grapsa

Professor, Cardiovascular Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Julia Grapsa, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Harvard Medical School (HMS and HSDM)

Ana G Almeida, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Lisbon University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aswan Heart Centre

Aswān, , Egypt

Site Status RECRUITING

University of Lisbon

Lisbon, , Portugal

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt Portugal

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Shehab Anwer, MD

Role: CONTACT

+41788816333

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Susy Kotit, MD PhD

Role: primary

+201000000

Ana G Almeida, MD PhD

Role: primary

+0000000000

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VHD-W Registry

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Valvular Heart Disease Registry
NCT03488732 RECRUITING
Tricuspid Regurgitation in the ElderlY
NCT05784883 ACTIVE_NOT_RECRUITING
Predictors of RV Dysfunction After BPV
NCT07191093 ACTIVE_NOT_RECRUITING
China Valve Registry Study-1
NCT02623907 UNKNOWN
German Aortic Valve Registry
NCT01165827 UNKNOWN